Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Janssen,Daratumumab IV (with bortezomib and dexamethasone),"Multiple myeloma, relapsed or refractory, 2nd line",Daratumumab IV (with bortezomib and dexamethasone),Options for investment,,Oncology Agents and Immunosuppressants
